Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).Citation formats

  • External authors:
  • Eric D Bateman
  • Kenneth R Chapman
  • Anthony D D'Urzo
  • Eduard Molins
  • Anne Leselbaum
  • Esther Garcia Gil

Standard

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). / Bateman, Eric D; Chapman, Kenneth R; Singh, Dave; D'Urzo, Anthony D; Molins, Eduard; Leselbaum, Anne; Gil, Esther Garcia.

In: Respiratory research, Vol. 16, 2015.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bateman, Eric D ; Chapman, Kenneth R ; Singh, Dave ; D'Urzo, Anthony D ; Molins, Eduard ; Leselbaum, Anne ; Gil, Esther Garcia. / Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). In: Respiratory research. 2015 ; Vol. 16.

Bibtex

@article{26560e0551fa4c4a933c7aea1b07e866,
title = "Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).",
abstract = "BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity",
author = "Bateman, {Eric D} and Chapman, {Kenneth R} and Dave Singh and D'Urzo, {Anthony D} and Eduard Molins and Anne Leselbaum and Gil, {Esther Garcia}",
year = "2015",
doi = "10.1186/s12931-015-0250-2",
language = "English",
volume = "16",
journal = "Respiratory research",
issn = "1465-9921",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT).

AU - Bateman, Eric D

AU - Chapman, Kenneth R

AU - Singh, Dave

AU - D'Urzo, Anthony D

AU - Molins, Eduard

AU - Leselbaum, Anne

AU - Gil, Esther Garcia

PY - 2015

Y1 - 2015

N2 - BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity

AB - BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta2-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and is approved in the European Union as a maintenance treatment. The effect of this combination on symptoms of COPD and exacerbations is less well established. We examined these outcomes in a pre-specified analysis of pooled data from two 24-week, double-blind, parallel-group, active- and placebo-controlled, multicentre, randomised Phase III studies (ACLIFORM and AUGMENT). METHODS: Patients ≥40 years with moderate to severe COPD (post-bronchodilator forced expiratory volume in 1 s [FEV1]/forced vital capacity

U2 - 10.1186/s12931-015-0250-2

DO - 10.1186/s12931-015-0250-2

M3 - Article

VL - 16

JO - Respiratory research

JF - Respiratory research

SN - 1465-9921

ER -